Previous Close | 7.95 |
Open | 7.92 |
Bid | 6.58 x 800 |
Ask | 8.74 x 900 |
Day's Range | 7.73 - 8.00 |
52 Week Range | 6.58 - 17.05 |
Volume | |
Avg. Volume | 10,245 |
Market Cap | 549.6M |
Beta (5Y Monthly) | 0.80 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.58 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.12 |
Subscribe to Yahoo Finance Plus to view Fair Value for VALN
Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). There are currently no preventive vaccines or effective treatments available against ZIKV. As such, this mosquito-borne disease remains a public health threat and is i
Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.24-0157 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC). Valneva’s 2023 Universal Registration Document – available in its entirety in French – includes the Company’s 2023 Annual Fina
Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript March 20, 2024 Valneva SE misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $0.2. VALN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Joshua Drumm: Thank you. Hello, and thank […]